OCBN / 30KalGene Pharmaceuticals KalGene / Angiogenic Signalling Laboratory / Biomarker Imaging Research Laboratory / KalGene Pharmaceuticals Inc. / CIMTEC / Research Institute’s Biomarker Imaging Research Laboratory / /
Continent
North America / Europe / /
Country
Canada / North America / Europe / /
Currency
USD / /
Event
Diplomatic Relations / /
Facility
Sunnybrook Research Institute / Sunnybrook Research Institute’s Biomarker Imaging Research Laboratory / Queen’s University / /
IndustryTerm
digital pathology algorithms / high-tech jobs / medical imaging landscape / immunohistochemistry imaging / medical imaging innovations / project management services / cancer therapeutics / technology development / laboratory services / medical imaging technology / precision medicine tools / treatment of a broad range of human diseases / /
MedicalCondition
cancer / KalGene’s advanced cancer / metastatic disease / aggressive cancers / breast / colon and brain cancer / human diseases / /
MedicalTreatment
cancer therapeutics / /
Organization
Sunnybrook Research Institute / Queen’s University / Department of Pathology and Molecular Medicine / Centre for Imaging Technology Commercialization / /
Person
John Gillard / Harriet Feilotter / Dan Dumont / Bart Sullivan / Nathan Yoganathan / Martin Yaffe / Ken Evans / /
Position
CEO / Principal Investigator / President and Chief Scientific Officer / /
ProvinceOrState
Ontario / /
Technology
genomics / digital pathology algorithms / antibodies / medical imaging technology / medical imaging / /
FOR IMMEDIATE RELEASE KalGene Pharmaceuticals, Sunnybrook Research Institute, Ontario Cancer Biomarker Network and CIMTEC announce multi-year collaboration to tackle aggressive cancers. London, Ontario, June 12, 2014 –